257 related articles for article (PubMed ID: 18341039)
21. Combination antifungal therapy: where are we now, and where are we going?
Marr K
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):24-9. PubMed ID: 15651179
[TBL] [Abstract][Full Text] [Related]
22. Caspofungin in combination with amphotericin B against Candida glabrata.
Barchiesi F; Spreghini E; Fothergill AW; Arzeni D; Greganti G; Giannini D; Rinaldi MG; Scalise G
Antimicrob Agents Chemother; 2005 Jun; 49(6):2546-9. PubMed ID: 15917570
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of micafungin for the treatment of candidemia.
Andes D; Safdar N
Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):662-4. PubMed ID: 16247615
[No Abstract] [Full Text] [Related]
24. New options for treatment of candidaemia in critically ill patients.
Ruhnke M; Hartwig K; Kofla G
Clin Microbiol Infect; 2008 May; 14 Suppl 4():46-54. PubMed ID: 18430129
[TBL] [Abstract][Full Text] [Related]
25. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
[TBL] [Abstract][Full Text] [Related]
26. Disseminated infection due to Candida guilliermondii in a patient with AML(M4). Case study.
Pânzaru C; Dan M; Burcoveanu C; Mereuţă A; Buiuc D
Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):727-30. PubMed ID: 17571574
[TBL] [Abstract][Full Text] [Related]
27. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species.
Nishi I; Sunada A; Toyokawa M; Asari S; Iwatani Y
J Infect Chemother; 2009 Feb; 15(1):1-5. PubMed ID: 19280292
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of liposomal amphotericin B against four species of Candida biofilms in an experimental mouse model of intravascular catheter infection.
Fujimoto K; Takemoto K
J Infect Chemother; 2018 Dec; 24(12):958-964. PubMed ID: 30209024
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
30. Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome.
Atkinson BJ; Lewis RE; Kontoyiannis DP
Med Mycol; 2008 Sep; 46(6):541-6. PubMed ID: 19180749
[TBL] [Abstract][Full Text] [Related]
31. [Guidelines for the management of deep mycosis in neutropenic patients].
Yoshida M
Nihon Ishinkin Gakkai Zasshi; 2004; 45(4):209-15. PubMed ID: 15550917
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment of Candida krusei fungemia with amphotericin B and caspofungin.
Olver WJ; Scott F; Shankland GS
Med Mycol; 2006 Nov; 44(7):655-7. PubMed ID: 17071561
[TBL] [Abstract][Full Text] [Related]
33. [Clinical use of micafungin for the treatment of invasive candidiasis in critical ill patients].
Pozo-Laderas JC
Rev Iberoam Micol; 2009 Mar; 26(1):69-74. PubMed ID: 19463281
[TBL] [Abstract][Full Text] [Related]
34. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
[TBL] [Abstract][Full Text] [Related]
35. Experience with caspofungin in the treatment of persistent fungemia in neonates.
Natarajan G; Lulic-Botica M; Rongkavilit C; Pappas A; Bedard M
J Perinatol; 2005 Dec; 25(12):770-7. PubMed ID: 16222348
[TBL] [Abstract][Full Text] [Related]
36. Successful Treatment of Breakthrough Trichosporon asahii Fungemia by the Combination Therapy of Fluconazole and Liposomal Amphotericin B in a Patient with Follicular Lymphoma.
Itoh K; Iwasaki H; Negoro E; Shigemi H; Tokimatsu I; Tsutani H; Yamauchi T
Mycopathologia; 2021 Mar; 186(1):113-117. PubMed ID: 33389484
[TBL] [Abstract][Full Text] [Related]
37. Triple antifungal therapy for severe systemic candidiasis allowed performance of allogeneic stem cell transplantation.
Gahn B; Schub N; Repp R; Gramatzki M
Eur J Med Res; 2007 Aug; 12(8):337-40. PubMed ID: 17933709
[TBL] [Abstract][Full Text] [Related]
38. Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials.
Horn DL; Ostrosky-Zeichner L; Morris MI; Ullmann AJ; Wu C; Buell DN; Kovanda LL; Cornely OA
Eur J Clin Microbiol Infect Dis; 2010 Feb; 29(2):223-9. PubMed ID: 20013016
[TBL] [Abstract][Full Text] [Related]
39. Clinical features, antifungal susceptibility, and outcome of Candida guilliermondii fungemia: An experience in a tertiary hospital in mid-Taiwan.
Tseng TY; Chen TC; Ho CM; Lin PC; Chou CH; Tsai CT; Wang JH; Chi CY; Ho MW
J Microbiol Immunol Infect; 2018 Aug; 51(4):552-558. PubMed ID: 28625801
[TBL] [Abstract][Full Text] [Related]
40. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.
Kuse ER; Chetchotisakd P; da Cunha CA; Ruhnke M; Barrios C; Raghunadharao D; Sekhon JS; Freire A; Ramasubramanian V; Demeyer I; Nucci M; Leelarasamee A; Jacobs F; Decruyenaere J; Pittet D; Ullmann AJ; Ostrosky-Zeichner L; Lortholary O; Koblinger S; Diekmann-Berndt H; Cornely OA;
Lancet; 2007 May; 369(9572):1519-1527. PubMed ID: 17482982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
